Article in Gene & protein in disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Kenneth BlumDivision of Clinical Neurology, The Blum Institute of Neurogenetics and Behavior, Austin, Texas, United States of America.ORCID 0000-0001-6727-803X
Eric R BravermanDivision of Clinical Neurology, The Blum Institute of Neurogenetics and Behavior, Austin, Texas, United States of America.ORCID 0000-0001-5525-8314
Alireza SharafshahCellular and Molecular Research Center, School of Medicine, Guilin University of Medical Sciences, Rasht, Iran.ORCID 0000-0001-8048-9587
Igor ElmanDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.ORCID 0000-0002-1345-2677
Kai-Uwe LewandrowskiDivision of Personalized Pain Therapy Research and Education, Center for Advanced Spine Care of Southern Arizona, Tucson, Arizona, United States of America.ORCID 0000-0001-7842-2914
Abdalla BowirratDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.ORCID 0000-0001-8185-0688
Albert PinhasovDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.ORCID 0000-0001-8116-4565
Panayotis K ThanosDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.ORCID 0000-0001-9784-731X
Mark S GoldDepartment of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America.ORCID 0000-0003-4713-3751
Catherine A DennenDepartment of Family Medicine, Jefferson Health Northeast, Philadelphia, Pennsylvania, United States of America.ORCID 0009-0003-7059-8386
Edward J ModestinoDepartment of Psychology, Curry College, Milton, Massachusetts, United States of America.ORCID 0000-0001-7611-5144
Rajendra D BadgaiyanDepartment of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio, United States of America.ORCID 0000-0001-5586-5114
David BaronDivision of Addiction Research and Education, Center for Sports, Exercise, and Mental Health, Western University of Health Sciences, Pomona, California, United States of America.ORCID 0000-0001-7670-2613
Brian FuehrleinDepartment of Psychiatry, Yale University School of Medicine, New Haven, United States of America.ORCID 0000-0002-3202-8089
Daniel SippleM Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States of America.ORCID 0009-0003-6516-5260
John Wesson AshfordDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, United States of America.ORCID 0000-0001-9600-6471
Keerthy SunderDepartment of Medicine, Riverside School of Medicine, University of California, Riverside, California, United States of America.ORCID 0009-0004-2361-3384
Milan MakaleDepartment of Radiation Oncology, University of California San Diego, La Jolla, California, United States of America.ORCID 0000-0001-5414-0517
Kevin MurphyDepartment of Radiation Oncology, University of California San Diego, La Jolla, California, United States of America.
Nicole JafariDepartment of Applied Clinical Psychology, The Chicago School of Professional Psychology, Los Angeles, United States of America.ORCID 0000-0001-7762-9673
Foojan ZeineDepartment of Health Science, California State University at Long Beach, Long Beach, California, United States of America.ORCID 0009-0006-7709-5580
Aryeh R PollackDivision of Clinical Neurology, The Blum Institute of Neurogenetics and Behavior, Austin, Texas, United States of America.
Alexander P L LewandrowskiDivision of Clinical Neurology, The Blum Institute of Neurogenetics and Behavior, Austin, Texas, United States of America.
Jag KhalsaDepartment of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America.
Funding
Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
Artificially increasing dopamine transmission is the common mechanism by which substances with addictive potential lead to addiction. A key area of research in neurobiology is the role of dopamine. Significant advancements have been made in uncovering the intracellular signaling pathways that mediate both dopamine's immediate effects and its long-term influence on brain function. Recent discoveries have also highlighted specific molecules that could serve as potential therapeutic targets for neurological and psychiatric disorders. While understanding several important caveats, we believe dopamine acts as a master regulator of brain circuitry across major chromosomes mapping the mental health genome. This view may have important clinical relevance, emphasizing the critical role of dopaminergic activity across the genome. Importantly, we are cognizant that dopamine does not work in insolation, and its finite actions are due to a highly interactive network (known as the brain reward cascade), involving at least seven other major neurotransmitters.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring dopamine as the master regulator of brain circuitry and mental health genome. · full record | OpenQuestion